Differential expression of microtubule-associated protein 2 in melanocytic skin lesions

American Journal of Clinical Pathology

Volumn 131, Issue 5, 2009, Pages 710-714

  Gambichler, Thilo ^a   Rotterdam, Sebastian ^a   Radkowski, Katharina ^a   Altmeyer, Peter ^a   Kreuter, Alexander ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Malignant melanoma; Melanocytic nevus; Microtubule associated protein

Indexed keywords

ANTIBODY; MICROTUBULE ASSOCIATED PROTEIN 2; MICROTUBULE ASSOCIATED PROTEIN 2 ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; MAP2 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; BENIGN NEVUS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; CANCER SUSCEPTIBILITY; DYSPLASTIC NEVUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MELANOCYTE; MELANOCYTIC NEVUS; MELANOCYTIC SKIN LESION; MELANOMA; METASTASIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN DEFECT; SUPERFICIAL CANCER; SUPERFICIAL SPREADING MELANOMA; DISEASE COURSE; METABOLISM; MIDDLE AGED; PATHOLOGY; PIGMENTED NEVUS; SKIN TUMOR;

DISEASE PROGRESSION; DYSPLASTIC NEVUS SYNDROME; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTES; MELANOMA; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM STAGING; NEVUS, PIGMENTED; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 65349157639     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPR84ULYVMNJHG     Document Type: Article

References (25)

1. Cummins DL, Cummins JM, Pantle H, et al. Cutaneous malignant melanoma. Mayo Clin Proc. 2006;81:500-507.
2. Skender-Kalnenas TM, English DR, Heenan PJ. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? J Am Acad Dermatol. 1995;33:1000-1007.
3. Gimotty PA, Botbyl J, Soong SJ, et al. A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2005;23:8065-8075.
4. Sangueza OP, Requena L. Neoplasms with neural differentiation: a review, part II: malignant neoplasms. Am J Dermatopathol. 1998;20:89-102.
5. Khare VK, Albino AP, Reed JA. The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions. J Cutan Pathol. 1998;25:2-10.
6. Dhillon AP, Rode J, Leathem A. Neurone specific enolase: an aid to the diagnosis of melanoma and neuroblastoma. Histopathology. 1982;6:81-92.
7. Fang D, Hallman J, Sangha N, et al. Expression of microtubule- associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma. Am J Pathol. 2001;158:2107-2115.
8. Soltani MH, Pichardo R, Song Z, et al. Microtubule-associated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma. Am J Pathol. 2005;166:1841-1850.
9. Liu Y, Saad RS, Shen SS, et al. Diagnostic value of microtubule- associated protein-2 (MAP-2) for neuroendocrine neoplasms. Adv Anat Pathol. 2003;10:101-106.
10. Matus A. Microtubule-associated proteins: their potential role in determining neuronal morphology. Annu Rev Neurosci. 1988;11:29-44.
11. Kobayashi N, Mundel P. A role of microtubules during the formation of cell processes in neuronal and non-neuronal cells. Cell Tissue Res. 1998;291:163-174.
12. Tojima T, Yamane Y, Takahashi M, et al. Acquisition of neuronal proteins during differentiation of NG108-15 cells. Neurosci Res. 2000;37:153-161.
13. Wiche G, Briones E, Koszka C, et al. Widespread occurrence of polypeptides related to microtubule-associated proteins (MAP-1 and MAP-2) in non-neuronal cells and tissues. EMBO J. 1984;3:991-998.
14. Harada A, Teng J, Takei Y, et al. MAP2 is required for dendrite elongation, PKA anchoring in dendrites, and proper PKA signal transduction. J Cell Biol. 2002;158:541-549.
15. Kalcheva N, Rockwood JM, Kress Y, et al. Molecular and functional characteristics of MAP-2a: ability of MAP-2a versus MAP-2b to induce stable microtubules in COS cells. Cell Motil Cytoskeleton. 1998;40:272-285.
16. Suzuki SO, Kitai R, Llena J, et al. MAP-2e, a novel MAP-2 isoform, is expressed in gliomas and delineates tumor architecture and patterns of infiltration. J Neuropathol Exp Neurol. 2002;61:403-412.
17. Liu Y, Sturgis CD, Grzybicki DM, et al. Microtubule-associated protein-2: a new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinoma. Mod Pathol. 2001;14:880-885.
18. Liu Y, Mangini J, Saad R, et al. Diagnostic value of microtubule- associated protein-2 in Merkel cell carcinoma. Appl Immunohistochem Mol Morphol. 2003;11:326-329.
19. Hendrix MJ, Seftor EA, Hess AR, et al. Molecular plasticity of human melanoma cells. Oncogene. 2003;22:3070-3075.
20. Ruiter D, Bogenrieder T, Elder D, et al. Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol. 2002;3:35-43.
21. Yang P, Hirose T, Hasegawa T, et al. Ultrastructural heterogeneity of acquired intradermal melanocytic nevus cells. Ultrastruct Pathol. 1996;20:255-261.
22. Brocker EB, Magiera H, Herlyn M. Nerve growth and expression of receptor for nerve growth factor in tumors of melanocyte origin. J Invest Dermatol. 1991;96:662-665.
23. Skelton HG, Smith KJ, Laskin WB, et al. Desmoplastic malignant melanoma. J Am Acad Dermatol. 1995;32:717-725.
24. de Almeida LS, Requena L, Rutten A, et al. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases. Am J Dermatopathol. 2008;30:207-215.
25. Bhat KM, Maddodi N, Shashikant C, et al. Transcriptional regulation of human MAP2 gene in melanoma: role of neuronal bHLH factors and Notch1 signaling. Nucleic Acids Res. 2006;34:3819-3832.